# Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

> **NCT02648724** · PHASE1,PHASE2 · COMPLETED · sponsor: **Symphogen A/S** · enrollment: 57 (actual)

## Conditions studied

- Oncology
- MET Gene Amplification
- NSCLC
- MET Gene Mutation
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Sym015

## Key facts

- **NCT ID:** NCT02648724
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02648724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02648724, "Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02648724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*